Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE